393 related articles for article (PubMed ID: 23307979)
21. Current treatment options for myeloma.
Terpos E; Rahemtulla A; Dimopoulos MA
Expert Opin Pharmacother; 2005 Jun; 6(7):1127-42. PubMed ID: 15957967
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.
Sivaraj D; Green MM; Li Z; Sung AD; Sarantopoulos S; Kang Y; Long GD; Horwitz ME; Lopez RD; Sullivan KM; Rizzieri DA; Chao NJ; Gasparetto C
Biol Blood Marrow Transplant; 2017 Feb; 23(2):262-268. PubMed ID: 27856369
[TBL] [Abstract][Full Text] [Related]
23. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
24. [A cure for multiple myeloma?].
Harousseau JL
Presse Med; 2006 Sep; 35(9 Pt 2):1288-90. PubMed ID: 16969322
[No Abstract] [Full Text] [Related]
25. Risk adapted post-transplant maintenance in multiple myeloma.
Vaxman I; Gertz M
Expert Rev Hematol; 2019 Feb; 12(2):107-118. PubMed ID: 30696304
[TBL] [Abstract][Full Text] [Related]
26. [Recent progress in diagnosis of and therapy for multiple myeloma].
Okamoto S
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1922-31. PubMed ID: 17037337
[No Abstract] [Full Text] [Related]
27. Treatment of newly diagnosed multiple myeloma.
Palumbo A; Magarotto V; Larocca A; Bringhen S; Falco P; Di Raimondo F; Baldini L; Boccadoro M
Curr Hematol Malig Rep; 2008 Apr; 3(2):107-14. PubMed ID: 20425454
[TBL] [Abstract][Full Text] [Related]
28. Treatment of myeloma in patients not eligible for transplantation.
Jagannath S
Curr Treat Options Oncol; 2005 May; 6(3):241-53. PubMed ID: 15869735
[TBL] [Abstract][Full Text] [Related]
29. Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Bhutani D; Zonder J; Valent J; Tageja N; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Lum L; Ratanatharathorn V; Uberti J; Abidi MH
Support Care Cancer; 2013 Sep; 21(9):2437-42. PubMed ID: 23591714
[TBL] [Abstract][Full Text] [Related]
30. [New drugs for myeloma].
Moreau P
Presse Med; 2006 Sep; 35(9 Pt 2):1303-8. PubMed ID: 16969325
[TBL] [Abstract][Full Text] [Related]
31. Latest advances and current challenges in the treatment of multiple myeloma.
Mahindra A; Laubach J; Raje N; Munshi N; Richardson PG; Anderson K
Nat Rev Clin Oncol; 2012 Feb; 9(3):135-43. PubMed ID: 22349016
[TBL] [Abstract][Full Text] [Related]
32. Advances in the autologous and allogeneic transplantation strategies for multiple myeloma.
Nishihori T; Alsina M
Cancer Control; 2011 Oct; 18(4):258-67. PubMed ID: 21976244
[TBL] [Abstract][Full Text] [Related]
33. Frontline treatment of multiple myeloma.
Fonseca R
Hematology; 2012 Apr; 17 Suppl 1():S101-4. PubMed ID: 22507793
[TBL] [Abstract][Full Text] [Related]
34. Management of double-refractory multiple myeloma.
Meadows JP; Mark TM
Curr Hematol Malig Rep; 2013 Dec; 8(4):253-60. PubMed ID: 23975677
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of myeloma in the elderly].
Garderet L; Isnard F; Gorin NC
Bull Cancer; 2008 May; 95 FMC Onco():F84-8. PubMed ID: 18511373
[TBL] [Abstract][Full Text] [Related]
36. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis.
Teh BW; Harrison SJ; Worth LJ; Thursky KA; Slavin MA
Eur J Cancer; 2016 Nov; 67():21-37. PubMed ID: 27592069
[TBL] [Abstract][Full Text] [Related]
37. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
38. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
39. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F
Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986
[TBL] [Abstract][Full Text] [Related]
40. Clinical update: novel targets in multiple myeloma.
Anderson KC
Semin Oncol; 2004 Dec; 31(6 Suppl 16):27-32; discussion 33. PubMed ID: 15799242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
